Senores Pharmaceuticals Ltd (SENORES) is currently trading at 1,133.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Senores Pharmaceuticals is a research-driven formulation company developing, manufacturing, and commercializing specialty and complex generic medicines for regulated markets, emerging markets, hospitals, and API customers. Its operations span the United States, India, Canada, the United Kingdom, and more than 40 emerging-market countries, supported by manufacturing facilities, R&D centers, subsidiaries, and strategic partnerships. The company delivered strong H1 FY27 operating momentum, with revenue increasing 30% to ₹372.5 crore and EBITDA rising 58.2% to ₹111.4 crore. EBITDA margin expanded 530 basis points to 29.9%, showing substantial operating leverage despite continued investments in Apnar, Zoraya, and Amerisyn. Regulated markets are the principal earnings engine, contributing 71% of H1 FY27 revenue and approximately 42% EBITDA margin. The portfolio has expanded to 64 approved ANDAs and 207 associated strengths, but 41 ANDAs and 153 strengths remain unlaunched, creating a substantial commercialization opportunity. Senores Pharmaceuticals is moving beyond a conventional B2B generic model through forward integration. Zoraya is intended to build a U.S. B2C platform, while Amerisyn provides access to federal and defense procurement, potentially improving control over commercialization and opening higher-barrier customer channels. The key investment tension is between strong profitability and cash conversion. H1 FY27 cash from operations improved to ₹38.5 crore, but investing outflows of ₹112.2 crore and higher borrowings reduced closing cash and equivalents to ₹18 crore, reflecting aggressive portfolio, facility, and subsidiary investments.

Over the past 52 weeks, Senores Pharmaceuticals Ltd has traded between a low of ₹708.10 and a high of ₹1,599.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Senores Pharmaceuticals Ltd has a market capitalization of approximately 5,611.86. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Senores Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 40.87 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 5,611.86 Cr, Senores Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Senores Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Senores Pharmaceuticals Ltd is 40.87. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Senores Pharmaceuticals filed its Q1 FY27 investor presentation with BSE and NSE on July 27, 2026.

Senores Pharmaceuticals is scheduled to consider and approve its Q2 FY27 and half-year results on October 29, 2026.

The company reported consolidated total income of ₹138.0 crore in Q1 FY26, up 72% year-on-year, as stated in the provided release and investor highlights.

The results are expected in the July to August 2026 window (indicative), in line with the broader NSE and BSE results season for the quarter ended June 2026.